Search

Your search keyword '"Parmar MKB"' showing total 11 results
Start Over Author "Parmar MKB" Database OAIster
11 results on '"Parmar MKB"'

1. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer

Author

Oza, B, Eisen, T, Frangou, E, Stewart, GD, Bex, A, Ritchie, AWS, Kaplan, R, Smith, B, Davis, ID, Stockler, MR, Albiges, L, Escudier, B, Larkin, J, Joniau, S, Hancock, B, Hermann, GG, Bellmunt, J, Parmar, MKB, Royston, P, Meade, A, Oza, B, Eisen, T, Frangou, E, Stewart, GD, Bex, A, Ritchie, AWS, Kaplan, R, Smith, B, Davis, ID, Stockler, MR, Albiges, L, Escudier, B, Larkin, J, Joniau, S, Hancock, B, Hermann, GG, Bellmunt, J, Parmar, MKB, Royston, P, and Meade, A

Abstract

PURPOSE: The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation of the 2003 Leibovich score using contemporary data from SORCE, an international, randomized trial of sorafenib after excision of primary RCC. METHODS: Data used to derive the 2003 Leibovich score were compared with contemporary data from SORCE. Discrimination and calibration of the metastasis-free survival outcome were assessed in data from patients with clear-cell RCC, using Cox proportional hazards regression, Kaplan-Meier curves, and calculation of Harrell's c indexes. Secondary analyses involved three important SORCE groups: patients with any non-clear-cell subtype, papillary, and chromophobe carcinomas. RESULTS: Four hundred seven recurrences occurred in 982 patients in the Leibovich cohort and 520 recurrences were recorded in 1,445 patients in the primary SORCE cohort. Clear discrimination between intermediate-risk and high-risk SORCE cohorts was shown; hazard ratio 2.74 (95% CI, 2.29 to 3.28), c-index 0.63 (95% CI, 0.61 to 0.65). A hazard ratio of 0.61 (95% CI, 0.53 to 0.70) confirmed poor calibration of the two cohorts. Discrimination was observed in secondary populations, with c-indexes of 0.64 (95% CI, 0.59 to 0.69) for non-clear-cell RCC, 0.63 (95% CI, 0.56 to 0.69) for papillary RCC, and 0.65 (95% CI, 0.55 to 0.76) for chromophobe RCC. CONCLUSION: The 2003 Leibovich score discriminates between intermediate-risk and high-risk clear-cell and non-clear-cell RCC groups in contemporary data, supporting its use for risk stratification in adjuvant clinical trials. Over time, metastasis-free survival for patients with locally advanced RCC has improved. Contemporary data from adjuvant RCC trials should be used to improve prognostication for patients with RCC.

Published
2022

2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Author

James, ND, Sydes, MR, Clarke, NW, Mason, MD, Dearnaley, DP, Spears, MR, Ritchie, AWS, Parker, CC, Russell, JM, Attard, G, De Bono, J, Cross, W, Jones, RJ, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, AJ, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, JD, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, DB, O'Sullivan, JM, Parikh, O, Peedell, C, Protheroe, A, Robinson, AJ, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, Parmar, MKB, James, ND, Sydes, MR, Clarke, NW, Mason, MD, Dearnaley, DP, Spears, MR, Ritchie, AWS, Parker, CC, Russell, JM, Attard, G, De Bono, J, Cross, W, Jones, RJ, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, AJ, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, JD, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, DB, O'Sullivan, JM, Parikh, O, Peedell, C, Protheroe, A, Robinson, AJ, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, and Parmar, MKB

Published
2015

3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Author

James, ND, Sydes, MR, Clarke, NW, Mason, MD, Dearnaley, DP, Spears, MR, Ritchie, AWS, Parker, CC, Russell, JM, Attard, G, De Bono, J, Cross, W, Jones, RJ, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, AJ, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, JD, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, DB, O'Sullivan, JM, Parikh, O, Peedell, C, Protheroe, A, Robinson, AJ, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, Parmar, MKB, James, ND, Sydes, MR, Clarke, NW, Mason, MD, Dearnaley, DP, Spears, MR, Ritchie, AWS, Parker, CC, Russell, JM, Attard, G, De Bono, J, Cross, W, Jones, RJ, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, AJ, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, JD, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, DB, O'Sullivan, JM, Parikh, O, Peedell, C, Protheroe, A, Robinson, AJ, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, and Parmar, MKB

Published
2015

4. Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

Author

Attard, G, Sydes, MR, Mason, MD, Clarke, NW, Aebersold, D, de Bono, JS, Dearnaley, DP, Parker, CC, Ritchie, AWS, Russell, JM, Thalmann, G, Cassoly, E, Millman, R, Matheson, D, Schiavone, F, Spears, MR, Parmar, MKB, James, ND, Attard, G, Sydes, MR, Mason, MD, Clarke, NW, Aebersold, D, de Bono, JS, Dearnaley, DP, Parker, CC, Ritchie, AWS, Russell, JM, Thalmann, G, Cassoly, E, Millman, R, Matheson, D, Schiavone, F, Spears, MR, Parmar, MKB, and James, ND

Abstract

There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure. © 2014 European Association of Urology.

Published
2014

5. Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

Author

Attard, G, Sydes, MR, Mason, MD, Clarke, NW, Aebersold, D, de Bono, JS, Dearnaley, DP, Parker, CC, Ritchie, AWS, Russell, JM, Thalmann, G, Cassoly, E, Millman, R, Matheson, D, Schiavone, F, Spears, MR, Parmar, MKB, James, ND, Attard, G, Sydes, MR, Mason, MD, Clarke, NW, Aebersold, D, de Bono, JS, Dearnaley, DP, Parker, CC, Ritchie, AWS, Russell, JM, Thalmann, G, Cassoly, E, Millman, R, Matheson, D, Schiavone, F, Spears, MR, Parmar, MKB, and James, ND

Abstract

There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure. © 2014 European Association of Urology.

Published
2014

6. Clinical trials in ovarian carcinoma : study methodology

Author

Vermorken, JB, Parmar, MKB, Brady, MF, Eisenhauer, EA, Högberg, Thomas, Ozols, RF, Rochon, J, Rustin, GJS, Sagae, S, Verheijen, RHM, Vermorken, JB, Parmar, MKB, Brady, MF, Eisenhauer, EA, Högberg, Thomas, Ozols, RF, Rochon, J, Rustin, GJS, Sagae, S, and Verheijen, RHM

Published
2005

7. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer

Author

UCL, Royston, P, Parmar, MKB, Sylvester, Richard J., UCL, Royston, P, Parmar, MKB, and Sylvester, Richard J.

Abstract

Many models for clinical prediction (prognosis or diagnosis) are published in the medical literature every year but few such models find their way into clinical practice. The reason may be that since in most cases models have not been validated in independent data, they lack generality and/or credibility. In this paper we consider the situation in which several compatible, independent data sets relating to a given disease with a time-to-event endpoint are available for analysis. The aim is to construct and evaluate a single prognostic model. Building a multivariable model from the available prognostic factors is accomplished within the Cox proportional hazards framework, stratifying by study. Non-linear relationships with continuous predictors are modelled by using fractional polynomials. To assess the discrimination or separation of a survival model, we use the D statistic of Royston and Sauerbrei. D may be interpreted as the separation (log hazard ratio) between the survival distributions for two independent prognostic groups. To evaluate the generality of a prognostic model across the data sets, we propose 'internal-external cross-validation' on D: each study is omitted in turn, the model parameters are estimated from the remaining studies and D is evaluated in the omitted study. Because the linear predictor of a survival model tells only part of the story, we also suggest a method for investigating heterogeneity in the baseline distribution function across studies which involves fitting completely specified, flexible parametric survival models (Royston and Parmar). Our final models combine the prognostic index (obtained with stratification by study) with the pooled baseline survival distribution (estimated parametrically). By applying this methodology, we construct two prognostic scores in superficial bladder cancer. The simpler of the two scores is more suited to clinical application. We show that a three-group prognostic classification scheme based on either s

Published
2004

8. Letter to the editor

Author

Swart, A, Parmar, M, Harper, P, Colombo, N, Torri, V, Swart, AMC, Parmar, MKB, Swart, A, Parmar, M, Harper, P, Colombo, N, Torri, V, Swart, AMC, and Parmar, MKB

Published
2004

9. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Author

Parmar, M, Ledermann, J, Colombo, N, du Bois, A, Delaloye, J, Kristensen, G, Wheeler, S, Swart, A, Qian, W, Torri, V, Floriani, I, Jayson, G, Lamont, A, Tropé, C, Parmar, MKB, Ledermann, JA, Kristensen, GB, Swart, AM, Tropé, C., COLOMBO, NICOLETTA, Parmar, M, Ledermann, J, Colombo, N, du Bois, A, Delaloye, J, Kristensen, G, Wheeler, S, Swart, A, Qian, W, Torri, V, Floriani, I, Jayson, G, Lamont, A, Tropé, C, Parmar, MKB, Ledermann, JA, Kristensen, GB, Swart, AM, Tropé, C., and COLOMBO, NICOLETTA

Abstract

Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment.

Published
2003

10. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials

Author

Aabo, K, Adams, M, Adnitt, P, Alberts, DS, Athanazziou, A, Barley, V, Bell, DR, Bianchi, U, Bolis, G, Brady, MF, Brodovsky, HS, Bruckner, H, Buyse, M, Canetta, R, Chylak, V, Cohen, CJ, Colombo, N, Conte, PF, Crowther, D, Edmonson, JH, Gennatas, C, Gilbey, E, Gore, M, Guthrie, D, Kaye, SB, Laing, AH, Landoni, F, Leonard, RC, Lewis, C ; https://orcid.org/0000-0002-5790-8672, Liu, PY, Mangioni, C, Marsoni, S, Meerpohl, H, Omura, GA, Parmar, MKB, Pater, J, Pecorelli, S, Presti, M, Sauerbrei, W, Skarlos, DV, Smalley, RV, Solomon, HJ, Stewart, LA, Sturgeon, JFG, Tattersall, MHN, Wharton, JT, Ten Bokkel Huinink, WW, Tomirotti, M, Torri, W, Trope, C, Turbow, MM, Vermorken, JB, Webb, MJ, Wilbur, DW, Williams, CJ, Wiltshaw, E, Yeap, BY, Aabo, K, Adams, M, Adnitt, P, Alberts, DS, Athanazziou, A, Barley, V, Bell, DR, Bianchi, U, Bolis, G, Brady, MF, Brodovsky, HS, Bruckner, H, Buyse, M, Canetta, R, Chylak, V, Cohen, CJ, Colombo, N, Conte, PF, Crowther, D, Edmonson, JH, Gennatas, C, Gilbey, E, Gore, M, Guthrie, D, Kaye, SB, Laing, AH, Landoni, F, Leonard, RC, Lewis, C ; https://orcid.org/0000-0002-5790-8672, Liu, PY, Mangioni, C, Marsoni, S, Meerpohl, H, Omura, GA, Parmar, MKB, Pater, J, Pecorelli, S, Presti, M, Sauerbrei, W, Skarlos, DV, Smalley, RV, Solomon, HJ, Stewart, LA, Sturgeon, JFG, Tattersall, MHN, Wharton, JT, Ten Bokkel Huinink, WW, Tomirotti, M, Torri, W, Trope, C, Turbow, MM, Vermorken, JB, Webb, MJ, Wilbur, DW, Williams, CJ, Wiltshaw, E, and Yeap, BY

Abstract

The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.

Published
1998

11. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

Author

Parmar, M, Torri, V, Bonaventura, A, Bonazzi, C, Colombo, N, Delaloye, J, Marsoni, S, Mangioni, C, Sandercock, J, Sessa, C, Williams, C, Tinazzi, A, Flann, M, Geiser, K, Scorpiglione, N, Stewart, J, Chaves, J, Palmeiro, E, Curtain, A, Mccormack, T, Gennatas, C, Marras, F, Oppo, T, Balestrino, M, Malzoni, C, Malzoni, M, Belli, M, Geminiani, M, Crestani, G, Monaco, A, Vavala, V, Piatto, E, Barattini, G, Fornara, P, Chetri, M, Santeufemia, G, Artioli, F, Carone, D, Fanizza, G, Trentadue, R, Priolo, D, Scollo, P, Nigro, S, Petrina, M, Mastrantonio, P, Spanna, G, Zagni, R, Belloni, C, Colleoni, R, Redaelli, L, Cavagnini, A, Di Costanzo, G, Perroni, D, Arienti, S, Orfanotti, G, Cantoni, F, Secli, R, Bianchi, A, Martinello, R, Mollica, G, Maizzi, D, Picchiarelli, M, Fiorini, G, Borsani, M, Colombo, E, Garsia, S, Melgrati, L, Paggi, G, Brunenghi, G, Casini, M, Isa, L, Algeri, R, Prozio, G, Belfiore, G, Angelini, F, D'Aprile, M, Moreschi, M, Mauri, M, Natale, N, Senzani, F, Pavanato, G, Poggi, G, Garuti, G, Luerti, M, Cruciani, G, Pagano, F, Baccolo, M, Poddi, E, Bocciolone, L, Sabelli, M, Maggi, R, Restelli, C, D'Antona, A, Locatelli, M, Pessi, A, Raina, A, Chiari, S, Gabriele, A, Pittelli, M, Iacobelli, P, Dogliotti, L, Gorzegno, G, Musso, P, Vegna, G, Coco, G, Alletti, D, Picciotto, F, Lucchese, V, Epis, A, di Palumbo, V, Drudi, G, Ravaioli, A, Zampella, D, Morandi, M, Gorga, G, Zucchelli, C, Cariello, S, Galletto, L, Sussio, M, Massacesi, L, Massacesi, M, Carli, A, Tucci, E, Tajani, E, Corrado, G, Bumma, S, Durando, A, Massobrio, M, Sberveglieri, M, Biasio, M, Guercio, E, Jura, R, Danese, S, Wierdis, T, Farnelli, C, Tarantino, G, Grassi, R, Repetti, F, Rocchi, B, Grampa, M, Ercoli, A, Griso, C, Signori, E, Zanini, L, Presti, M, Klimek, M, Urbanski, K, Biswas, A, Viegas, O, Kochli, O, Dreher, E, Fey, M, Beck, G, Ludin, J, Bonnefoi, H, Krauer, F, Bauer, J, Delmore, G, Furrer, C, Lorenz, U, Thurlimann, B, Bronz, L, Sanna, P, Wyss, D, Goldhirsch, A, Gyr, T, Leidi, L, Pastorelli, G, Pagani, O, Rey, P, Hailer, U, Benz, J, Kaye, S, Reed, N, Symonds, R, Atkinson, R, Axford, A, Rustin, G, Seckl, M, Green, J, Scott, I, Guthrie, D, Harper, P, Calman, F, Dobbs, H, Weir, P, Cassoni, A, Lederman, J, Souhami, R, Bozzino, J, Adab, F, Redman, C, Scoble, J, Paterson, M, Daniel, F, Cowley, N, Spooner, D, Hong, A, Mcillmurray, M, Hendy Ibbs, P, Hall, V, Iveson, T, Whitehouse, J, Garry, R, Lamont, A, Robinson, A, Trask, C, Clubb, A, Murrell, D, Newman, G, Wilkins, M, Goldthorp, W, Roberts, J, Radstone, D, Whipp, M, Ledermann, J, Pater, J, Buyse, M, Omura, G, Parmar, MKB, McCormack, T, McIllmurray, M, Omura, G., COLOMBO, NICOLETTA, Parmar, M, Torri, V, Bonaventura, A, Bonazzi, C, Colombo, N, Delaloye, J, Marsoni, S, Mangioni, C, Sandercock, J, Sessa, C, Williams, C, Tinazzi, A, Flann, M, Geiser, K, Scorpiglione, N, Stewart, J, Chaves, J, Palmeiro, E, Curtain, A, Mccormack, T, Gennatas, C, Marras, F, Oppo, T, Balestrino, M, Malzoni, C, Malzoni, M, Belli, M, Geminiani, M, Crestani, G, Monaco, A, Vavala, V, Piatto, E, Barattini, G, Fornara, P, Chetri, M, Santeufemia, G, Artioli, F, Carone, D, Fanizza, G, Trentadue, R, Priolo, D, Scollo, P, Nigro, S, Petrina, M, Mastrantonio, P, Spanna, G, Zagni, R, Belloni, C, Colleoni, R, Redaelli, L, Cavagnini, A, Di Costanzo, G, Perroni, D, Arienti, S, Orfanotti, G, Cantoni, F, Secli, R, Bianchi, A, Martinello, R, Mollica, G, Maizzi, D, Picchiarelli, M, Fiorini, G, Borsani, M, Colombo, E, Garsia, S, Melgrati, L, Paggi, G, Brunenghi, G, Casini, M, Isa, L, Algeri, R, Prozio, G, Belfiore, G, Angelini, F, D'Aprile, M, Moreschi, M, Mauri, M, Natale, N, Senzani, F, Pavanato, G, Poggi, G, Garuti, G, Luerti, M, Cruciani, G, Pagano, F, Baccolo, M, Poddi, E, Bocciolone, L, Sabelli, M, Maggi, R, Restelli, C, D'Antona, A, Locatelli, M, Pessi, A, Raina, A, Chiari, S, Gabriele, A, Pittelli, M, Iacobelli, P, Dogliotti, L, Gorzegno, G, Musso, P, Vegna, G, Coco, G, Alletti, D, Picciotto, F, Lucchese, V, Epis, A, di Palumbo, V, Drudi, G, Ravaioli, A, Zampella, D, Morandi, M, Gorga, G, Zucchelli, C, Cariello, S, Galletto, L, Sussio, M, Massacesi, L, Massacesi, M, Carli, A, Tucci, E, Tajani, E, Corrado, G, Bumma, S, Durando, A, Massobrio, M, Sberveglieri, M, Biasio, M, Guercio, E, Jura, R, Danese, S, Wierdis, T, Farnelli, C, Tarantino, G, Grassi, R, Repetti, F, Rocchi, B, Grampa, M, Ercoli, A, Griso, C, Signori, E, Zanini, L, Presti, M, Klimek, M, Urbanski, K, Biswas, A, Viegas, O, Kochli, O, Dreher, E, Fey, M, Beck, G, Ludin, J, Bonnefoi, H, Krauer, F, Bauer, J, Delmore, G, Furrer, C, Lorenz, U, Thurlimann, B, Bronz, L, Sanna, P, Wyss, D, Goldhirsch, A, Gyr, T, Leidi, L, Pastorelli, G, Pagani, O, Rey, P, Hailer, U, Benz, J, Kaye, S, Reed, N, Symonds, R, Atkinson, R, Axford, A, Rustin, G, Seckl, M, Green, J, Scott, I, Guthrie, D, Harper, P, Calman, F, Dobbs, H, Weir, P, Cassoni, A, Lederman, J, Souhami, R, Bozzino, J, Adab, F, Redman, C, Scoble, J, Paterson, M, Daniel, F, Cowley, N, Spooner, D, Hong, A, Mcillmurray, M, Hendy Ibbs, P, Hall, V, Iveson, T, Whitehouse, J, Garry, R, Lamont, A, Robinson, A, Trask, C, Clubb, A, Murrell, D, Newman, G, Wilkins, M, Goldthorp, W, Roberts, J, Radstone, D, Whipp, M, Ledermann, J, Pater, J, Buyse, M, Omura, G, Parmar, MKB, McCormack, T, McIllmurray, M, Omura, G., and COLOMBO, NICOLETTA

Abstract

A series of meta-analyses of randomised controlled trials raised the question of whether the three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) was more or less effective than optimal-dose single-agent carboplatin for women with advanced ovarian cancer.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results